4-乙基-2,6-雙(吡啶-3-基亞甲基)環(huán)己酮
| 中文名稱 | 4-乙基-2,6-雙(吡啶-3-基亞甲基)環(huán)己酮 |
|---|---|
| 中文同義詞 | (2E,6E)-4-乙基-2,6-二(3-吡啶基亞甲基)環(huán)己酮;4-乙基-2,6-雙(吡啶-3-基亞甲基)環(huán)己酮;MCB-613游離態(tài);化合物MCB613,10 MM DMSO 溶液;源葉 S80133 MCB-613;源葉 S80133 MCB-613 |
| 英文名稱 | MCB-613 |
| 英文同義詞 | 4-ethyl-2,6-bis(pyridin-3-ylmethylene)cyclohexanone;(2E,6E)-4-Ethyl-2,6-bis(3-pyridinylmethylene)cyclohexanone;MCB-613;CS-2522;(2E,6E)-4-ethyl-2,6-bis(pyridin-3-ylmethylidene)cyclohexan-1-one;Cyclohexanone, 4-ethyl-2,6-bis(3-pyridinylmethylene)-, (2E,6E)-;MCB-613, 10 mM in DMSO |
| CAS號(hào) | 1162656-22-5 |
| 分子式 | C20H20N2O |
| 分子量 | 304.39 |
| EINECS號(hào) | |
| 相關(guān)類別 | 合成材料中間體;標(biāo)準(zhǔn)品;API |
| Mol文件 | 1162656-22-5.mol |
| 結(jié)構(gòu)式 |  |
4-乙基-2,6-雙(吡啶-3-基亞甲基)環(huán)己酮 性質(zhì)
| 沸點(diǎn) | 510.4±50.0 °C(Predicted) |
|---|---|
| 密度 | 1.159±0.06 g/cm3(Predicted) |
| 儲(chǔ)存條件 | Sealed in dry,Room Temperature |
| 溶解度 | 不溶于水； ≥13.2 mg/mL，溶于 DMSO，溫和加熱； ≥9.26 mg/mL，乙醇溶液，超聲波 |
| 形態(tài) | 固體 |
| 酸度系數(shù)(pKa) | 4.36±0.12(Predicted) |
| 顏色 | 淺黃至黃色 |
| InChI | InChI=1S/C20H20N2O/c1-2-15-9-18(11-16-5-3-7-21-13-16)20(23)19(10-15)12-17-6-4-8-22-14-17/h3-8,11-15H,2,9-10H2,1H3/b18-11+,19-12+ |
| InChIKey | MMBSCBVEHMETSA-GDAWTGGTSA-N |
| SMILES | C1(=O)/C(=C/C2=CC=CN=C2)/CC(CC)C/C/1=C\C1=CC=CN=C1 |
MCB-613 是一種有效的類固醇受體共激活因子 (SRC) 小分子“刺激物” (SMS)，超刺激 SRCs 的轉(zhuǎn)錄活性。
MCB-613 增加了 SRC 與其他共激活因子的相互作用，并顯著誘導(dǎo) ER 應(yīng)激與活性氧 (ROS) 的產(chǎn)生相結(jié)合。
MCB-613 是一種 SMS，通過(guò)過(guò)度刺激 SRC 致癌程序，靶向癌基因用作抗癌藥物。MCB-613 (6-8 μM; 24 hours) activates endogenous MMP13 mRNA expression in MDA-MB-231 cells. MCB-613 (2-10 μM; 4 hours) leads to proteasome dysfunction and ER stress, the induction of the markers for unfolded protein response (UPR), including the phosphorylation of eIF2α and IRE1α as well as the induction of ATF4 protein expression. MCB-613 (0-7 μM; 4 hours) affects SRC-3 KO and WT HeLa cell viability, SRC-3 WT HeLa cell is more affected by MCB-613 compared with KO cells.
RT-PCR
| Cell Line: | MDA-MB-231 cells |
| Concentration: | 6 μM; 8 μM |
| Incubation Time: | 24 hours |
| Result: | Increased MMP13 mRNA expression. |
Western Blot Analysis
| Cell Line: | HeLa cells |
| Concentration: | 2 μM; 4 μM; 6 μM; 8 μM; 10 μM |
| Incubation Time: | 24 hours |
| Result: | Induced the p-eIF2α, p-IRE1α, and ATF-4 protein expression. |
Cell Viability Assay
| Cell Line: | SRC-3 KO and WT HeLa cells |
| Concentration: | 3 μM; 4 μM; 5 μM; 6 μM; 7 μM |
| Incubation Time: | 24 hours |
| Result: | Decreased SRC-3 KO and WT HeLa cell viability. |
MCB-613 (intravenous injection; 20 mg/kg; 3 times/week; 7 weeks) significantly and dramatically stalls the growth of the tumor compared with the control group and causes no obvious animal toxicity
| Animal Model: | MCF-7 breast cancer mouse xenograft model (athymic nude mice by injecting MCF-7 cells into mammary fat pads) |
| Dosage: | 20 mg/kg |
| Administration: | Intravenous injection; 20 mg/kg; 3 times/week; 7 weeks |
| Result: | Inhibited tumor growth in vivo. |
安全信息
| 更新日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
|---|---|---|---|---|---|
| 2025/12/22 | HY-19625 | 4-乙基-2,6-雙(吡啶-3-基亞甲基)環(huán)己酮 MCB-613 | 1162656-22-5 | 1 mg | 440元 |
| 2025/12/22 | HY-19625 | 4-乙基-2,6-雙(吡啶-3-基亞甲基)環(huán)己酮 MCB-613 | 1162656-22-5 | 10mM * 1mLin DMSO | 737元 |